Key facts for NCD 150.7
- Benefit category
- Physicians' Services
- Effective date
- 09/27/1999
- Transmittal
- n/a
- Versions published
- 1
- Manual chapter
- 150
- NCD Manual (Pub. 100-03)
TL;DR
NCD 150.7 sets Medicare's national policy for prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents under the benefit category "Physicians' Services", effective 09/27/1999. The medical effectiveness of the above therapies has not been verified by scientifically controlled studies. Accordingly, reimbursement for these modalities should be denied on the ground that they are not reasonable and necessary as required by §1862(a)(1)… It has been revised once since publication and binds every Medicare Administrative Contractor nationally.
Indications and limitations of coverage
The medical effectiveness of the above therapies has not been verified by scientifically controlled studies. Accordingly, reimbursement for these modalities should be denied on the ground that they are not reasonable and necessary as required by §1862(a)(1) of the Act.
Text reproduced from the CMS Medicare Coverage Database record for NCD 150.7 version 1. View the original on cms.gov.
Revision history
9/27/1999 - Issued decision memo maintaining national noncoverage policy.
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
How QuickIntell applies NCD 150.7
QuickAuth checks the ordered service and diagnosis against NCD and LCD criteria before the encounter, QuickCode validates the diagnosis pairing on the claim, and QuickRCM routes CARC 50 denials with the policy text and the covered-code list attached so the appeal starts with evidence.
Frequently asked questions — NCD 150.7
What does NCD 150.7 cover?
The medical effectiveness of the above therapies has not been verified by scientifically controlled studies. Accordingly, reimbursement for these modalities should be denied on the ground that they are not reasonable and necessary as required by §1862(a)(1) of the Act. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 150.7 take effect?
The current version (1) is effective 09/27/1999. This is the only published version.
Does a Local Coverage Determination override NCD 150.7?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-02. Verify against the primary file before billing or contracting decisions.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.